49146
document
[ Efficacy of naftopidil in patients with overactive bladder associated with benign prostatic hyperplasia : prospective randomized controlled study to compare differences in efficacy between morning and evening medication ] . A total of 100 patients with benign prostatic hyperplasia ( BPH ) and overactive bladder ( OAB ) symptoms ( BPH/OAB ) , enrolled between June 2006 to March 2008 , were randomly divided into 2 groups of morning medication ( M ) and evening medication ( E ) groups , then 50 mg of naftopidil was given once a day after breakfast or supper for 8 weeks . Data were available for efficacy analysis on 80 patients ( M group ; 43 , E group ; 37 ) . Naftopidil significantly improved the overall international prostatic symptom score ; from 19.2±7.9 to 11.7±5.8 in the M group and from 19.4±6.4 to 12.3±6.8 in the E group ( p < 0.0001 ) , QOL score from 4.9±0.8 to 3.2±1.4 in the M group and from 5.0±0.8 to 3.6±1.3 in the E group ( p < 0.0001 ) , and OAB symptom score from 7.8±2.6 to 5.0±2.5 in the M group ( p < 0.0001 ) and from 8.6±2.9 to 5.8± 3.3 in the E group ( p < 0.0001 ) . There was no significant difference in the incidence of adverse effects between the M group ( 6.1 % ) and E group ( 2.2 % ) . These results suggest that naftopidil improves storage symptoms as well as voiding symptoms regardless of timing of administration .
49147
Intervention_Pharmacological
naftopidil
49148
Intervention_Pharmacological
naftopidil
49149
Intervention_Pharmacological
Naftopidil
49150
Outcome_Other
overall international prostatic symptom score
49151
Participant_Condition
overactive bladder associated with benign prostatic hyperplasia
49152
Participant_Sample-size
100
49153
Participant_Condition
benign prostatic hyperplasia ( BPH ) and overactive bladder ( OAB ) symptoms
49154
Participant_Condition
BPH/OAB